

Sélection des publications 2015 de l'équipe 1

Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguín V, Rivière S, Corre R, Bailly S, Paintaud G.
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
MAbs. 2015, 7 : 630-637

Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, Madelaine-Chambin I, Thiebaut JB, Polivka M, Paintaud G, Culine S, Janin A.
Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer.
J Clin Oncol. 2014 Dec 29. pii: JCO.2012.44.8894. [Epub ahead of print]

Chaigne B, Watier H.
Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?
J Allergy Clin Immunol. 2015, 136 : 814-816

Dannepond C, Maruani A, Mchet L, Ternant D, Paintaud G, Samimi M.
Serum Infliximab Concentrations in Psoriatic Patients Treated with Infliximab: A Systematic Review.
Acta Derm Venereol. 2015, 95 : 401-406

Fizesan M, Boin C, Aujoulat O, Newinger G, Ghergus D, Watier H, Lustig H, Ojeda-Urbe M.
Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.
J Oncol Pharm Pract. 2016, 22 : 188-192

Gatault P, Brachet G, Ternant D, Degenne D, Récipon G, Barbet C, Gyan E, Gouilleux-Gruart V, Bordes C, Farrell A, Halimi JM, Watier H.
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.
MAbs.2015, 7 : 1205-1211

Gupta N, Culina S, Meslier Y, Dimitrov J, Arnoult C, Delignat S, Gangadharan B, Lecerf M, Justesen S, Gouilleux-Gruart V, Salomon BL, Scott DW, Kaveri SV, Mallone R, Lacroix-Desmazes S.
Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance.
Sci Transl Med. 2015 Feb 18;7(275):275ra21

Jary M, Vernerey D, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, Godet Y, Kim S, Bouché O, Fratte S, Gonçalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C.
Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.
Cancer Epidemiol Biomarkers Prev. 2015,24 : 603-612

Karnes JH, Cronin RM, Rollin J, Teumer A, Pouplard C, Shaffer CM, Blanquicett C, Bowton EA, Cowan JD, Mosley JD, Van Driest SL, Weeke PE, Wells QS, Bakchoul T, Denny JC, Greinacher A, Gruel Y, Roden DM.
A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.
Thromb Haemost. 2015, 113 : 772-781

Morel A, Passot C, Arnoult C, Dumans A, Beaumont E, Gouilleux-Gruart V, Roingeard P, Blanchard E.
The neonatal Fc receptor (FcRn) does not modulate hepatitis C virus neutralization.
J Gen Virol. 2015, 96 : 1062-1066

Rollin J, Pouplard C, Cheng Sung H, Leroux D, Saada A, Gouilleux-Gruart V, Thibault G, Gruel Y.
Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2.
Blood. 2015,125 : 2397-2404

Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerré T, Xavier LL, Vittecoq O, Goupille P, Mulleman D, Paintaud G.
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.
Br J Clin Pharmacol. 2015, 79 : 286-297.

Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G.
Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.
Clin Pharmacokinet. 2015, 54 : 1107-1123

Ternant D, Berkane Z, Picon L, Gouilleux-Gruart V, Colombel JF, Allez M, Louis E, Paintaud G.
Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.
Clin Pharmacokinet. 2015, 54 : 551-562